PK-PD of antifungal drugs: from preclinical data to clinical applications

被引：0
|
作者：
Mazzei, T. [1 ]
机构：
[1] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2013年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
下载
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers
    Li, Yun-fei
    Wang, Kun
    Yin, Fang
    He, Ying-chun
    Huang, Ji-han
    Zheng, Qing-shan
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (11) : 1424 - 1430
  • [32] ROLE OF MYOSTATIN PATHWAY IN MUSCLE GROWTH: KEY LEARNINGS FROM RETROSPECTIVE ANALYSIS OF MYO-029 PRECLINICAL AND CLINICAL DATA THRU PK/PD MODELING.
    Singh, P.
    Gordi, T.
    Bosley, J.
    Rong, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S131 - S131
  • [33] Generation of a novel preclinical PK/PD model provides insights into PARP inhibitor clinical monotherapy activity
    O'Connor, M.
    Cadogan, E.
    Leo, E.
    Hughes, A.
    Learoyd, M.
    Xu, H.
    Li, J.
    Yates, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Assessment of romosozumab efficacy in the treatment of postmenopausal osteoporosis: Results from a mechanistic PK-PD mechanostat model of bone remodeling
    Martin, Madge
    Sansalone, Vittorio
    Cooper, David M. L.
    Forwood, Mark R.
    Pivonka, Peter
    BONE, 2020, 133
  • [35] Chronoimmunology: from preclinical assessments to clinical applications
    Henrik Oster
    David W. Ray
    Seminars in Immunopathology, 2022, 44 : 149 - 151
  • [36] Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases
    Moore, Jason N.
    Poon, Lucas
    Pahwa, Sonia
    Bensman, Timothy
    Wei, Xiaohui
    Danielsen, Zhixia Yan
    Jang, Seong
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (06) : 1337 - 1343
  • [37] Clinical pharmacology of asparaginases in the United States: Asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients
    Avramis, Vassilios I.
    Spence, Susan A.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (04) : 239 - 247
  • [38] A Pharmacokinetic-Pharmacodynamic (PK-PD)-Based Treatment Strategy With Ceftriaxone (CTRX) for Acute Cholangitis That Was Proven to Be Effective in Actual Clinical Practice
    Toki, Masao
    Yamaguchi, Yasuharu
    Nakamura, Kenji
    Takahashi, Shin'ichi
    GASTROENTEROLOGY, 2011, 140 (05) : S448 - S449
  • [39] Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance
    Mukherjee, Aparna
    Gowtham, Lakshminarayanan
    Kabra, Sushil Kumar
    Lodha, Rakesh
    Velpandian, Thirumurthy
    INDIAN JOURNAL OF PEDIATRICS, 2024,
  • [40] Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of etanercept in patients with juvenile rheumatoid arthritis (JRA) using a dichotomous clinical endpoint.
    Yim, D
    Zhou, H
    Peck, CC
    Lee, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P92 - P92
12345